Shots:

• The P-III SELECT-PsA 1 & 2 trials evaluate Rinvoq (15/30mg) vs PBO in patients with active PsA & axial involvement who have a history of intolerance or inadequate response to one non-biologic & biologic DMARD
• The results showed a greater clinical response related to axial across both studies compared to Humira across all BASDAI & ASDAS EPs in SELECT-PsA 1 @24wks. & proportion of patients achieve ASDAS CII (69.8% vs 54.1%). The safety profile was consistent with previously reported studies & no new safety risks were observed
• Rinvoq (15mg) has received the US FDA’s approval for RA & EC’s approval for RA, PsA & AS. The therapy has received EC’s approval for 15 & 30mg doses to treat AD

  Ref: PR Newswire | Image: abbvie